Skip to main content
. 2022 Oct 5;379:e071752. doi: 10.1136/bmj-2022-071752

Table 2.

Characteristics of potential safety signals identified from the US Food and Drug Administration (FDA) Adverse Event Reporting System publicly reported by the FDA, 2014-15

  No (%) of signals
Total No of signals 82 (100)
Associated product type:  
 Drug 66 (80.5)
 Biologic 16 (19.5)
Therapeutic area:  
 Autoimmune/musculoskeletal 3 (3.7)
 Cancer 10 (12.2)
 Cardiovascular, diabetes, or lipids 19 (23.2)
 Dermatology 1 (1.2)
 Infectious disease 13 (15.9)
 Neurology 3 (3.7)
 Other 28 (34.1)
 Psychiatry 5 (6.1)
Associated adverse event type:
 Cardiovascular adverse event 7 (8.5)
 Non-cardiovascular adverse event 75 (91.5)